Organon & Co. has entered into a merger agreement to acquire Dermavant Sciences Ltd. for up to $1.2 billion, including an initial payment of $175 million and additional milestone payments based on FDA approval and sales performance of Dermavant's product VTAMA. The merger is expected to close in Q4 2024, subject to regulatory approvals and customary closing conditions.